Table 1.

Comparators and treatment sequences per population

Population	Comparators	Sequences
1a. Moderate RA, as monotherapy after two or more cDMARD failures in patients who are methotrexate ineligible	Placebo/BSC	1 BSC
		Upon progression to severe sequence 2a:
		1 Adalimumab
		2 Abatacept SC
1b. Moderate RA, as combination therapy after two or more cDMARD failures in patients who are methotrexate eligible	Placebo/BSC	1 BSC
		Upon progression to severe sequence 2b:
		1 Adalimumab
		2 Rituximab
		3 Tocilizumab SC
2a. Severe RA, as first-line advanced monotherapy therapy after failure of two or more cDMARDs in severe RA, for patients who are methotrexate ineligible	Adalimumab, etanercept, tocilizumab SC and baricitinib (each as monotherapy)	1 Abatacept SC
		2 BSC
2.b Severe RA, as first-line advanced therapy after failure of two or more cDMARDs	Adalimumab, etanercept, baricitinib (all + methotrexate)	1 Rituximab + methotrexate
		2 Tocilizumab SC + methotrexate
		3 BSC
		If rituximab contraindicated (IL-6):
		1 Tocilizumab SC + methotrexate
		2 BSC
		If rituximab contraindicated (CD80):
		1 Abatacept SC + methotrexate
		2 BSC
3a. After first-line advanced therapy failure	Abatacept SC, baricitinib and tofacitinib (each as monotherapy)	1 BSC
3b. After first-line advanced therapy failure in patients who are rituximab ineligible	Abatacept SC, baricitinib, sarilumab and tocilizumab SC (all + methotrexate)	1 BSC
4. After first-line advanced therapy failure in patients who are rituximab eligible	Rituximab + methotrexate	1 Tocilizumab SC + methotrexate
		2 BSC
5. After failure of rituximab in combination with methotrexate	Tocilizumab SC and sarilumab (all + methotrexate)	1 BSC

BSC best supportive care, cDMARD conventional disease-modifying antirheumatic drugs, CD80 cluster of differentiation 80, IL interleukin, RA rheumatoid arthritis, SC subcutaneously